Modeling heart failure in animal models for novel drug discovery and development

被引:10
|
作者
Janssen, Paul M. L. [1 ,2 ,3 ]
Elnakish, Mohammad T. [1 ,2 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Physiol & Cell Biol, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
Animal model; human heart failure; ischemia; hypertension; contraction; LEFT-VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION MODEL; CONTRACTILE DYSFUNCTION; ANGIOTENSIN-II; CARDIAC-FUNCTION; CANINE MODEL; IN-VIVO; FORCE; MOUSE; RAT;
D O I
10.1080/17460441.2019.1582636
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: When investigating drugs that treat heart diseases, it is critical when choosing an animal model for the said model to produce data that is translatable to the human patient population, while keeping in mind the principles of reduction, refinement, and replacement of the animal model in the research. Areas covered: In this review, the authors focus on mammalian models developed to study the impact of drug treatments on human heart failure. Furthermore, the authors address human patient variability and animal model invariability as well as the considerations that need to be made regarding choice of species. Finally, the authors discuss some of the most common models for the two most prominent human heart failure etiologies; increased load on the heart and myocardial ischemia. Expert opinion: In the authors' opinion, the data generated by drug studies is often heavily impacted by the choice of species and the physiologically relevant conditions under which the data are collected. Approaches that use multiple models and are not restricted to small rodents but involve some verification on larger mammals or on human myocardium, are needed to advance drug discovery for the very large patient population that suffers from heart failure.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [21] Alternative Animal and Non-Animal Models for Drug Discovery and Development: Bonus or Burden?
    Irlan Almeida Freires
    Janaina de Cássia Orlandi Sardi
    Ricardo Dias de Castro
    Pedro Luiz Rosalen
    Pharmaceutical Research, 2017, 34 : 681 - 686
  • [22] Animal models of major depressive disorder and the implications for drug discovery and development
    Demin, Konstantin A.
    Sysoev, Maxim
    Chernysh, Maria V.
    Savva, Anna K.
    Koshiba, Mamiko
    Wappler-Guzzetta, Edina A.
    Song, Cai
    De Abreu, Murilo S.
    Leonard, Brian
    Parker, Matthew O.
    Harvey, Brian H.
    Tian, Li
    Vasar, Eero
    Strekalova, Tatyana
    Amstislavskaya, Tamara G.
    Volgin, Andrey D.
    Alpyshov, Erik T.
    Wang, Dongmei
    Kalueff, Allan V.
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (04) : 365 - 378
  • [23] Human Engineered Heart Tissue Models for Disease Modeling and Drug Discovery
    Tani, Hidenori
    Tohyama, Shugo
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [24] Novel drug targets in clinical development for heart failure
    Melvin George
    Muthukumar Rajaram
    Elangovan Shanmugam
    Thangavel Mahalingam VijayaKumar
    European Journal of Clinical Pharmacology, 2014, 70 : 765 - 774
  • [25] Novel drug targets in clinical development for heart failure
    George, Melvin
    Rajaram, Muthukumar
    Shanmugam, Elangovan
    VijayaKumar, Thangavel Mahalingam
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (07) : 765 - 774
  • [26] The oxytocin system in drug discovery for autism: Animal models and novel therapeutic strategies
    Modi, Meera E.
    Young, Larry J.
    HORMONES AND BEHAVIOR, 2012, 61 (03) : 340 - 350
  • [27] Role of animal models in oncology drug discovery
    R Kumar
    Breast Cancer Research, 5 (Suppl 1)
  • [28] Inaugural Charles River World Congress on Animal Models in Drug Discovery and Development
    Jay A. Berzofsky
    Lauren Gerard Koch
    Steven L. Britton
    Shaochen Chen
    Wei Zhu
    Xuanyi Ma
    Anthony G. Comuzzie
    Laetitia Devy-Dimanche
    Ryan Feaver
    Jan Grimm
    Christoph Hock
    Roger M. Nitsch
    James B. Hoying
    Aldons J. Lusis
    Francesco Marincola
    Josue Samayoa
    Tolga Turan
    David A. Pearce
    Antti Nurmi
    Tuulia Huhtala
    Artem Shatillo
    Jukka Puoliväli
    Taneli Heikkinen
    Timo Bragge
    Kimmo Lehtimäki
    Arun J. Sanyal
    Kevin Strange
    D. Lansing Taylor
    Mark Miedel
    Shanhang Jia
    Alex Soto-Guterriez
    Andrew Stern
    Albert Gough
    Journal of Translational Medicine, 15 (Suppl 3)
  • [29] Use of animal models for genomic drug discovery
    Tsujimoto, G
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 54P - 54P
  • [30] Animal models for opioid addiction drug discovery
    Grenald, Shaness A.
    Largent-Milnes, Tally M.
    Vanderah, Todd W.
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (11) : 1345 - 1354